Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer.

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC ACS Applied Electronic Materials Pub Date : 2024-01-01 DOI:10.2174/0113895575287242240129120002
Ekta Shirbhate, Vaibhav Singh, Aditya Mishra, Varsha Jahoriya, Ravichandran Veerasamy, Amit K Tiwari, Harish Rajak
{"title":"Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer.","authors":"Ekta Shirbhate, Vaibhav Singh, Aditya Mishra, Varsha Jahoriya, Ravichandran Veerasamy, Amit K Tiwari, Harish Rajak","doi":"10.2174/0113895575287242240129120002","DOIUrl":null,"url":null,"abstract":"<p><p>Chemotherapy is still the major method of treatment for many types of cancer. Curative cancer therapy is hampered significantly by medication resistance. Acidic organelles like lysosomes serve as protagonists in cellular digestion. Lysosomes, however, are gaining popularity due to their speeding involvement in cancer progression and resistance. For instance, weak chemotherapeutic drugs of basic nature permeate through the lysosomal membrane and are retained in lysosomes in their cationic state, while extracellular release of lysosomal enzymes induces cancer, cytosolic escape of lysosomal hydrolases causes apoptosis, and so on. Drug availability at the sites of action is decreased due to lysosomal drug sequestration, which also enhances cancer resistance. This review looks at lysosomal drug sequestration mechanisms and how they affect cancer treatment resistance. Using lysosomes as subcellular targets to combat drug resistance and reverse drug sequestration is another method for overcoming drug resistance that is covered in this article. The present review has identified lysosomal drug sequestration as one of the reasons behind chemoresistance. The article delves deeper into specific aspects of lysosomal sequestration, providing nuanced insights, critical evaluations, or novel interpretations of different approaches that target lysosomes to defect cancer.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113895575287242240129120002","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

Abstract

Chemotherapy is still the major method of treatment for many types of cancer. Curative cancer therapy is hampered significantly by medication resistance. Acidic organelles like lysosomes serve as protagonists in cellular digestion. Lysosomes, however, are gaining popularity due to their speeding involvement in cancer progression and resistance. For instance, weak chemotherapeutic drugs of basic nature permeate through the lysosomal membrane and are retained in lysosomes in their cationic state, while extracellular release of lysosomal enzymes induces cancer, cytosolic escape of lysosomal hydrolases causes apoptosis, and so on. Drug availability at the sites of action is decreased due to lysosomal drug sequestration, which also enhances cancer resistance. This review looks at lysosomal drug sequestration mechanisms and how they affect cancer treatment resistance. Using lysosomes as subcellular targets to combat drug resistance and reverse drug sequestration is another method for overcoming drug resistance that is covered in this article. The present review has identified lysosomal drug sequestration as one of the reasons behind chemoresistance. The article delves deeper into specific aspects of lysosomal sequestration, providing nuanced insights, critical evaluations, or novel interpretations of different approaches that target lysosomes to defect cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
靶向溶酶体:对抗癌症化疗抗药性的策略
化疗仍然是治疗多种癌症的主要方法。抗药性严重阻碍了癌症的治疗。溶酶体等酸性细胞器是细胞消化的主角。然而,由于溶酶体在癌症进展和抗药性方面的加速参与,溶酶体正日益受到人们的关注。例如,碱性弱化疗药物可渗透溶酶体膜,并以阳离子状态保留在溶酶体中,而溶酶体酶的细胞外释放会诱发癌症,溶酶体水解酶的细胞外逸会导致细胞凋亡等。由于溶酶体的药物螯合作用,药物在作用部位的可用性降低,这也增强了癌症的抗药性。本综述探讨溶酶体药物螯合机制及其如何影响癌症耐药性。利用溶酶体作为亚细胞靶点来对抗耐药性和逆转药物螯合是本文涉及的另一种克服耐药性的方法。本综述认为溶酶体药物螯合是导致化疗耐药性的原因之一。文章深入探讨了溶酶体螯合的具体方面,提供了针对溶酶体缺陷癌症的不同方法的细微见解、批判性评价或新颖诠释。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
期刊最新文献
Hyperbaric oxygen treatment promotes tendon-bone interface healing in a rabbit model of rotator cuff tears. Oxygen-ozone therapy for myocardial ischemic stroke and cardiovascular disorders. Comparative study on the anti-inflammatory and protective effects of different oxygen therapy regimens on lipopolysaccharide-induced acute lung injury in mice. Heme oxygenase/carbon monoxide system and development of the heart. Hyperbaric oxygen for moderate-to-severe traumatic brain injury: outcomes 5-8 years after injury.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1